论文信息 - Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial. - 字舞流文

Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial.

Joon-Oh Park | M. Buyse | Y. Bang | D. Slamon | M. Press | P. Hoff | P. Salman | S. Qin | A. Sobrero | Jin Li | Y. Shparyk | S. Protsenko | H. Chung | Jian-ming Xu | K. Jeziorski | K. Afenjar | Tomomi Kaneko | A. Kemner | S. Santillana | T. Kaneko | Jian‐ming Xu